RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
+0.75%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$911M
AUM Growth
+$911M
(-5%)
Cap. Flow
-$18.5M
Cap. Flow
% of AUM
-2.03%
Top 10 Holdings %
Top 10 Hldgs %
30.91%
Holding
97
New
4
Increased
33
Reduced
45
Closed
9
Top Buys
| 1 |
UnitedHealth
UNH
|
$17.9M |
| 2 |
McKesson
MCK
|
$8.23M |
| 3 |
Cooper Companies
COO
|
$7.72M |
| 4 |
Abbott
ABT
|
$6.74M |
| 5 |
Cigna
CI
|
$5.72M |
Top Sells
| 1 |
Eli Lilly
LLY
|
$32.2M |
| 2 |
Johnson & Johnson
JNJ
|
$17.7M |
| 3 |
Medtronic
MDT
|
$9.11M |
| 4 |
RVNC
Revance Therapeutics, Inc.
RVNC
|
$6.48M |
| 5 |
Pfizer
PFE
|
$6.46M |
Sector Composition
| 1 | Healthcare | 95.19% |
| 2 | Industrials | 0.49% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
76
Intellia Therapeutics
NTLA
$1.26B
| $1.8M | 0.2% |
50,000
| – | – |
|
|
IGMS
77
DELISTED
IGM Biosciences
IGMS
| $1.62M | 0.18% |
95,000
+45,000
| +90% | +$766K |
|
78
Rigel Pharmaceuticals
RIGL
$710M
| $1.55M | 0.17% |
1,157,593
-67,488
| -6% | -$90.4K |
|
79
Esperion Therapeutics
ESPR
$490M
| $1.5M | 0.17% |
900,000
| – | – |
|
80
Allogene Therapeutics
ALLO
$249M
| $1.49M | 0.16% |
300,000
-40,000
| -12% | -$199K |
|
81
Mersana Therapeutics
MRSN
$34.8M
| $1.4M | 0.15% |
350,000
-50,000
| -13% | -$200K |
|
82
ESSA Pharma
EPIX
$11.2M
| $1.05M | 0.12% |
356,500
-18,500
| -5% | -$54.6K |
|
83
Stereotaxis
STXS
$246M
| $953K | 0.1% |
493,618
-303,712
| -38% | -$586K |
|
84
Axsome Therapeutics
AXSM
$6.09B
| $908K | 0.1% |
+15,000
| New | +$908K |
|
85
Nkarta
NKTX
$149M
| $680K | 0.07% |
200,000
| – | – |
|
86
Sangamo Therapeutics
SGMO
$161M
| $534K | 0.06% |
314,157
-505,843
| -62% | -$860K |
|
87
Rapid Micro Biosystems
RPID
$105M
| $165K | 0.02% |
127,152
-172,848
| -58% | -$225K |
|
|
OSH
88
DELISTED
Oak Street Health, Inc.
OSH
| – | – |
-250,000
| Closed | -$5.38M |
|
|
GTHX
89
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| – | – |
-370,000
| Closed | -$2.01M |
|
90
Teladoc Health
TDOC
$1.37B
| – | – |
-130,000
| Closed | -$3.07M |
|
91
Phathom Pharmaceuticals
PHAT
$843M
| – | – |
-235,210
| Closed | -$2.64M |
|
92
Envista
NVST
$3.37B
| – | – |
-163,800
| Closed | -$5.52M |
|
93
Nektar Therapeutics
NKTR
$543M
| – | – |
-550,000
| Closed | -$1.24M |
|
|
94
Eli Lilly
LLY
$661B
| – | – |
-88,000
| Closed | -$32.2M |
|
95
Ionis Pharmaceuticals
IONS
$9.64B
| – | – |
-50,000
| Closed | -$1.89M |
|
|
96
Johnson & Johnson
JNJ
$429B
| – | – |
-100,000
| Closed | -$17.7M |
|